<DOC>
	<DOCNO>NCT01197053</DOCNO>
	<brief_summary>This study aim show Epicutaneous Immunotherapy peanut protein safe efficacious desensitize child peanut allergy .</brief_summary>
	<brief_title>Epicutaneous Immunotherapy Peanut Allergy Children</brief_title>
	<detailed_description>Peanut allergy common allergy United Sates , prevalence general population high 1 % . Peanut allergy start childhood , prevalence child double past 5 year , barely 20 % allergic child outgrow allergy So far , treatment available peanut allergy avoidance peanut injectable epinephrine allergic systemic reaction start . Immunotherapy method currently available show limitation use important safety issue . Hence , important unmet medical need efficient safe treatment peanut allergy . DBV Technologies , French biotech company develop Epicutaneous Delivery System , call Viaskin® , method base deliver precise quantity allergens upper layer skin , i.e . epidermis without passage vascularise dermis . Avoiding contact allergens bloodstream confer epicutaneous immunotherapy ( EPIT ) high level safety systemic reaction circumvent . The goal pilot study demonstrate epicutaneous immunotherapy ( EPIT ) Viaskin® safe efficacious desensitization peanut-allergic child , i.e . increase quantity peanut proteins consume symptom-free . Fifty-two ( 52 ) child 5 17 year age confirm peanut allergy baseline double blind placebo-controlled food challenge ( DBPCFC ) ( react cap value 250 mg peanut protein ) randomize 1 1 treat either DBV712 , Viaskin® disk load 100 mcg peanut protein ( active treatment ) , placebo , Viaskin® disk load placebo formulation devoid peanut . Each child receive one application one Viaskin® skin every day repeatedly 6 month blind manner , follow 12-month open treatment DBV712 ; placebo child cross-over first 6 month treatment also receive active treatment . A DBPCFC peanut conduct every 6 month treatment assess efficacy treatment . Safety assess whole study period . Skin test , peanut-specific IgE IgG4 occur select visit</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Male Female 5 17 year age enrollment An efficient contraceptive method girl childbearing potential . Acceptable method include sexual abstinence , oral , injectable contraceptive method , intra uterine device . Negative pregnancy test girl childbearing potential . Child document allergy peanut , i.e . peanutspecific IgE ( &gt; 5KU/L , ImmunoCAP method ) and/or positive skin prick test peanut ( wheal diameter ≥ 8mm ) . Child able consume cumulate quantity peanut proteins &lt; 250 mg baseline DBPCFC . Child his/her legal representative ( ) provide sign consent form assent form . Child his/her legal representative ( ) whose family social condition allow understand protocol agree comply long term study requirement . Exclusion criterion : Child consider severely allergic peanut : history severe anaphylaxis peanut ( hypotension , loss consciousness , severe bradycardia , respiratory cardiac arrest require admission emergency room ) . Child peanutspecific IgE &lt; 5 KU/L whose skin prick test peanut give wheal diameter &lt; 8mm ) . Child participate participate therapeutic study last 3 month Pregnancy Breastfeeding Child generalize eczema Child immune deficiency Diabetic child Child allergic chocolate Child legal representative ( ) sign consent assent Child baseline DBPCFC Child react placebo baseline DBPCFC Child able consume &gt; 250 mg cumulate peanut protein baseline DBPCFC Child respiratory deficiency uncontrolled asthma . Child could discontinue oral I.V . antihistamine oral I.V . corticosteroid least week prior Visit 1 . Child important skin lesion preclude application disk . Child affiliate social security .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Peanut Allergy</keyword>
	<keyword>Food Allergy</keyword>
	<keyword>Epicutaneous Immunotherapy ( EPIT )</keyword>
	<keyword>Food Challenge</keyword>
</DOC>